TM

Troy W. McCall

Chief Commercial Officer at CROMSOURCE

As Chief Commercial Officer, Dr. McCall is responsible for the global commercial success of the organization. He currently oversees the Global Sales, Marketing, Corporate Communications, and Proposals functions to drive business growth and market share.

Dr. McCall brings more than twenty-five years of experience in the pharmaceutical and CRO industries, having worked for more than a decade each in increasingly senior positions in specialty pharma and life science services companies. He has a proven track record of success in leading and growing start-up, small, and medium-sized organizations. He has been a managing partner and/or CEO at four companies.

Throughout his career, Dr. McCall has consistently been successful in building value through a disciplined business approach which includes, but is not limited to, cost rationalization and expense management resulting in industry-leading margins, hands-on and effective engagement with clients, FDA, and other stakeholders, active participation with the sales and marketing organizations to significantly improve top-line results, and top-grading talent at all levels. He has extensive experience with growing and transforming companies and developing successful, sustainable organizations.

In addition to his roles in pharmaceutical and life science services companies, Dr. McCall has served as an advisor to private equity firms to support their investment activities, both for potential new investments as well as providing guidance to their existing portfolio companies. He also served as a Senior Advisor to The Reagan-Udall Foundation for the Food and Drug Administration where he led multiple initiatives supporting the FDA’s mission to promote and protect public health. One such initiative was the Innovation in Medical Evidence Development and Surveillance (IMEDS) program, a public-private partnership comprised of a variety of stakeholders (FDA, regulated industry, academia, advocates, and others) with the goal of optimizing the way in which large observational healthcare datasets are managed to improve the safety of marketed medical products.


Org chart